Katsumi Nakatomi
Ureshino, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.
Journal: Translational lung cancer research
Published: February 20, 2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 20, 2025
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 23, 2025
Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.
Journal: ESMO open
Published: June 06, 2025
A phase II clinical trial on the efficacy and safety of carboplatin plus nab-paclitaxel in chemotherapy-naive advanced or recurrent thymic epithelial tumors: protocol of Nab-TET.
Journal: Journal of thoracic disease
Published: May 31, 2025
Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 24, 2025
Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer.
Journal: International journal of cancer
Published: February 21, 2025
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.
Journal: Investigational new drugs
Published: December 13, 2024
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 19, 2024
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
Journal: BMC pulmonary medicine
Published: June 27, 2024
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study).
Journal: Translational lung cancer research
Published: June 15, 2024
Last Updated: 09/26/2026